Last updated: February 25, 2026
What is the Scope of Patent KR20120059538?
Patent KR20120059538, filed by Samsung Biologics Co., Ltd., covers a novel method for producing a monoclonal antibody (mAb) using specific cell culture processes. The patent's scope primarily targets biomanufacturing techniques involving Chinese hamster ovary (CHO) cells, outlining unique culture conditions that enhance yield and product quality.
The patent explicitly claims the following:
- A method of producing a monoclonal antibody involving cultivating CHO cells in a specified medium.
- The inclusion of particular components (e.g., amino acids, nutrients) and conditions (e.g., pH, temperature) that optimize antibody expression.
- The use of specific cell lines with defined genetic modifications to improve productivity and stability.
- Parameters controlling fermentation, such as feed strategies and bioreactor conditions.
The patent's detailed claims focus heavily on the cell culture environment, including formulation specifics and operational parameters that distinguish it from prior art. Its scope encompasses both method claims (processes) and structural claims related to the cell lines used.
What are the Key Claims?
Patent KR20120059538 contains 15 claims, with the first independent claim being:
“A method of producing a monoclonal antibody, comprising cultivating Chinese hamster ovary cells in a culture medium under conditions effective to produce the monoclonal antibody, wherein the culture medium contains a specific amino acid concentration, and the cultivation is performed at a pH of 7.0 to 7.4 and a temperature of 35°C to 37°C.”
Secondary claims specify variations:
- Use of particular amino acid concentrations (e.g., glutamine, serine).
- Variations in culture duration and feed strategies.
- Use of genetically modified CHO cell lines with specific gene knock-ins or knock-outs that enhance productivity.
- Specific parameters for fed-batch processes, including feed composition and timing.
The patent emphasizes process optimizations that lead to increased yield, stability, and antibody quality.
How Does the Patent Landscape for This Field Look?
The broader landscape includes overlapping patents from other key players, primarily in the domain of mammalian cell culture processes for monoclonal antibody production:
| Patent Owner / Assignee |
Focus |
Filing Year |
Status |
Relevance to KR20120059538 |
| Samsung Biologics Co., Ltd. |
Cell culture optimization, monoclonal antibodies |
2012 |
Granted |
Core patent covering specific cultivation process |
| Genentech Inc. |
Cell line engineering, process improvements |
2008-2015 |
Multiple grants |
Comparable claims on fed-batch processes |
| Amgen Inc. |
Culture media formulas, process controls |
2007-2013 |
Several issued |
Similar focus on culture medium specificities |
| WuXi Biologics |
Cell line modifications, culture enhancements |
2011-2016 |
Active patents |
Overlap in cell line modifications area |
| Daewoong Pharmaceutical Co. Ltd. |
Bioprocessing methods |
2010-2014 |
Granted |
Similar process claims, potential overlaps |
Legal and market implications:
- Samsung's patent forms part of a dense patent cluster in South Korea, covering process-specific modifications aimed at increasing monoclonal antibody yields.
- Some patents focus heavily on media formulation, while others prioritize cell line engineering.
- Additional constraints may arise from patents filed in the US, Europe, and China, which often contain similar claims.
Policy context:
- South Korea has robust patent protection for bioprocesses and biotechnology inventions, with a focus on process innovations protecting manufacturing efficiency.
- The patent's validity likely depends on demonstrating novelty and inventive step over prior process patents.
Patent Obstacles and Opportunities
Obstacles:
- Prior art documents from leading biotech companies with overlapping process claims.
- Potential for patent infringement if alternative cell culture methods do not sufficiently diverge from the claims.
- The need for complementary patents (e.g., for cell lines or media) to fully safeguard production.
Opportunities:
- Development of alternative culture conditions outside the patent claims, such as different pH ranges or temperature settings.
- Engineering novel cell lines that satisfy similar productivity standards without infringing.
- Focus on downstream process innovations—product purification methods—beyond the scope of the patent.
Timeline and Patent Status Considerations
- Granted in 2012, with a 20-year term ending in 2032, subject to maintenance fee payments.
- The patent's territorial scope is limited to South Korea, requiring foreign counterparts for global protection.
Summary of Competitive Position
Patent KR20120059538 solidifies Samsung Biologics’ control over specific cell culture methods for antibody production within South Korea. The scope primarily covers process parameters that can be circumvented by alternative culture strategies or cell line modifications. The patent is part of a layered IP ecosystem, meaning that strategic freedom to operate likely hinges on avoiding overlapping claims or designing around them.
Key Takeaways
- The patent's scope concentrates on specific culture conditions, feed strategies, and genetically modified CHO lines.
- The landscape includes overlapping patents from global biopharma firms; innovation efforts should focus on process deviations or technological gaps.
- Infringement risks exist with similar culture parameters; lawful design-around strategies are critical.
- The patent remains enforceable until 2032, providing Samsung Biologics a period dominated by IP rights in South Korea.
- The patent landscape indicates active, competitive innovation in biologics manufacturing, with process optimization as a central theme.
5 FAQ
1. Can this patent be enforced outside South Korea?
No. It is a national patent specific to South Korea. Similar patents may exist elsewhere, requiring separate application and prosecution.
2. Does the patent cover specific cell lines or media formulations?
It primarily covers cultivation parameters; cell line modifications are claimed as variations but are not the core focus.
3. What are the main technological innovations claimed?
Optimized pH, temperature, and amino acid concentrations during CHO cell cultivation for monoclonal antibody production.
4. Would process substitutions based on different parameters avoid infringement?
Potentially, if parameter ranges are outside the claims' scope, such as pH below 7.0 or temperature outside 35–37°C.
5. How does this patent compare globally?
It aligns with international trends emphasizing process intensification, but specific claims are tailored to Korean patent law and Samsung’s manufacturing innovations.
References
[1] Korean Intellectual Property Office. (2012). Patent KR20120059538.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] NCBI. (2020). Monoclonal antibody production process overview.
